ATE432506T1 - Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease - Google Patents

Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease

Info

Publication number
ATE432506T1
ATE432506T1 AT03761598T AT03761598T ATE432506T1 AT E432506 T1 ATE432506 T1 AT E432506T1 AT 03761598 T AT03761598 T AT 03761598T AT 03761598 T AT03761598 T AT 03761598T AT E432506 T1 ATE432506 T1 AT E432506T1
Authority
AT
Austria
Prior art keywords
drug
hiv
drug resistance
phenotypical
protease
Prior art date
Application number
AT03761598T
Other languages
English (en)
Inventor
Meyer Sandra De
Hilde Azijn
Bethune Marie-Pierre T M M G De
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE432506T1 publication Critical patent/ATE432506T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03761598T 2002-07-01 2003-06-30 Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease ATE432506T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39275302P 2002-07-01 2002-07-01
PCT/EP2003/050277 WO2004003817A1 (en) 2002-07-01 2003-06-30 Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance

Publications (1)

Publication Number Publication Date
ATE432506T1 true ATE432506T1 (de) 2009-06-15

Family

ID=30000930

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761598T ATE432506T1 (de) 2002-07-01 2003-06-30 Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease

Country Status (7)

Country Link
US (2) US7217506B2 (de)
EP (1) EP1520247B1 (de)
AT (1) ATE432506T1 (de)
AU (1) AU2003254500B2 (de)
CA (1) CA2490862A1 (de)
DE (1) DE60327768D1 (de)
WO (1) WO2004003817A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246859T3 (es) * 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
WO2002033638A2 (en) * 2000-10-20 2002-04-25 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US20050214744A1 (en) * 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
EP1522039B1 (de) * 2002-07-01 2008-06-04 Tibotec Pharmaceuticals Ltd. Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
EP1520247B1 (de) 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
US7372540B2 (en) * 2004-10-12 2008-05-13 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method
DK1856125T3 (da) 2005-02-25 2009-12-07 Tibotec Pharm Ltd Syntese af proteasehæmmerforstadie
EP1896618A4 (de) * 2005-05-27 2009-12-30 Monogram Biosciences Inc Verfahren und zusammensetzungen zur bestimmung der resistenz von hiv-1 gegen proteasehemmer
WO2007084618A2 (en) * 2006-01-19 2007-07-26 Monogram Biosciences, Inc. Method for determining resistance of hiv to protease inhibitor treatment
JP5297814B2 (ja) * 2006-02-03 2013-09-25 ビルコ・ビーブイビーエイ 量的ｈｉｖ表現型又は向性アッセイ

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US327742A (en) 1885-10-06 Machine for making nuts
GB2229340B (en) 1989-03-17 1994-02-09 Technophone Ltd Radio telephone system
GB8918226D0 (en) 1989-08-09 1989-09-20 Wellcome Found Dna assays
EP0428000A1 (de) 1989-11-03 1991-05-22 Abbott Laboratories Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität
US5235039A (en) 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
WO1993023574A1 (en) 1992-05-14 1993-11-25 Kozal Michael J Polymerase chain reaction assays for monitoring antiviral therapy
US6063562A (en) 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
US5685141A (en) 1995-12-26 1997-11-11 General Electric Company Lock for nozzle control in the event of hydraulic failure
EP0817866A1 (de) 1996-01-26 1998-01-14 Innogenetics N.V. Verfahren für den nachweis von drogen-induzierten mutationen in dem reverse transcriptase gen
PL186473B1 (pl) 1996-01-26 2004-01-30 Virco Nv Sposób oceny in vitro chemioterapii HIV u pacjentów HIV dodatnich oraz sposób oznaczania fenotypowej wrażliwości lekowej poszczególnych szczepów HIV u pacjenta na inhibitory co najmniej dwóch enzymówkodowanych przez gen pol HIV
DE69739645D1 (de) 1996-01-29 2009-12-17 Monogram Biosciences Inc Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening
JP3062459B2 (ja) 1996-08-14 2000-07-10 理化学研究所 ポリエステル重合酵素遺伝子及びポリエステルの製造方法
EP1082454A4 (de) 1998-05-26 2005-04-13 Virologic Inc Gerätschaft und verfahren zum überwachen von antiretroviraler therapie durch nicht-nukleosidische reverse transkriptase inhibition
AU4673399A (en) 1998-05-28 1999-12-13 Visible Genetics Inc. Use of polymorphisms as a predictor of drug-resistance mutations
JP4776775B2 (ja) 1998-06-23 2011-09-21 アメリカ合衆国 Ｈｉｖ感染哺乳動物を治療するための医薬組成物
JP2003503004A (ja) 1998-06-24 2003-01-28 バイロロジック・インコーポレイテッド ヌクレオチド逆転写酵素阻害剤抗レトロウイルス療法をモニターし、ｈｉｖ／ａｉｄｓの治療における治療決定をガイドする手段および方法
CA2330234A1 (en) 1998-06-24 1999-12-29 Innogenetics N.V. Method for detection of drug-selected mutations in the hiv protease gene
ES2246859T3 (es) 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
CA2375905A1 (en) 1999-06-22 2000-12-28 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
WO2000078994A1 (en) 1999-06-23 2000-12-28 The Penn State Research Foundation Compositions and methods for the quantification of sterol biosynthetic flux
DE60135366D1 (de) * 2000-04-18 2008-09-25 Virco Bvba Methode zur bestimmung der resistenz gegen medikamente
AU2001256318B8 (en) 2000-04-20 2007-03-22 Virco Bvba Method for mutation detection in HIV using pol sequencing
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
EP1352356B1 (de) 2000-06-08 2009-10-14 Virco Bvba Verfahren um die resistenz gegen ein therapeutisches agenz vorherzusagen unter verwendung neuronaler netze
CA2422815A1 (en) 2000-09-15 2002-03-21 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
EP1340075B1 (de) 2000-10-20 2009-01-28 Virco Bvba Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz
WO2002033638A2 (en) 2000-10-20 2002-04-25 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
JP2002199890A (ja) 2000-10-23 2002-07-16 Inst Of Physical & Chemical Res 生分解性ポリエステル合成酵素の改変方法
AU2002223052B2 (en) 2000-11-10 2007-09-20 Eurofins Viralliance, Inc. Novel method for analysing phenotypic characteristics of human immunodeficiency virus (HIV)
US7659404B2 (en) 2001-02-14 2010-02-09 Tibotec Pharmaceuticals Ltd. Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
US20050214744A1 (en) 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
EP1520247B1 (de) 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
EP1522039B1 (de) 2002-07-01 2008-06-04 Tibotec Pharmaceuticals Ltd. Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
WO2004022523A2 (en) 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
EP1605064A1 (de) 2004-06-07 2005-12-14 UMC Utrecht Holding B.V. HIV Varianten, welche einen neuen Resistenzmechanismus gegenüber Proteaseinhibitoren zeigen, diagnostische Assays zum Nachweis der Varianten, und Methoden zur Identifikation von Medikamenten, welche gegen die resistenten Varianten wirksam sind.

Also Published As

Publication number Publication date
US7217506B2 (en) 2007-05-15
US8592161B2 (en) 2013-11-26
AU2003254500B2 (en) 2009-11-19
US20070269816A1 (en) 2007-11-22
CA2490862A1 (en) 2004-01-08
DE60327768D1 (de) 2009-07-09
EP1520247A1 (de) 2005-04-06
EP1520247B1 (de) 2009-05-27
AU2003254500A1 (en) 2004-01-19
US20050233312A1 (en) 2005-10-20
WO2004003817A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
Juliano et al. Exposing malaria in-host diversity and estimating population diversity by capture-recapture using massively parallel pyrosequencing
EP1185712B8 (de) Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
Verrelli et al. Signatures of selection and gene conversion associated with human color vision variation
ATE432506T1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
Lythgoe et al. Shared SARS-CoV-2 diversity suggests localised transmission of minority variants
Mullick et al. Understanding mutation hotspots for the SARS-CoV-2 spike protein using Shannon Entropy and K-means clustering
SE0003286D0 (sv) Method and kit for human identification
WO2007061881A3 (en) Systems and methods for the biometric analysis of index founder populations
WO2003100557A3 (en) Computer systems and methods for subdividing a complex disease into component diseases
DE69423346D1 (de) Schnelles verfahren fur die dns sequenzierung und diagnostische anwendungen
ATE515575T1 (de) Verfahren und sonden für den nachweis von krebs
Pelkonen Lapsiperheiden voimavarat ja niiden vahvistaminen hoitotyon keinoin.
EP1565579A4 (de) Verfahren zur identifizierung des brustkrebsrisikos und behandlungen davon
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
ATE397669T1 (de) Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase
ES2609479T3 (es) Procedimiento implementado por ordenador y sistema informático para la identificación de organismos
MXPA03003476A (es) Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco.
WO2002022076A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
ATE400666T1 (de) Verwendung eines typ-iii-restriktionsenzyms zur isolierung von mehr als 25 nukleotide umfassenden sequenz-tags
ATE375400T1 (de) Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
WO2002099387A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
HUP0303491A2 (hu) Magas vérnyomás kvantitatív diagnosztikai elemzése
JP5065694B2 (ja) 遺伝子型判定結果の評価方法及び評価システム
Shrestha et al. Multiperson use of syringes among injection drug users in a needle exchange program: a gene-based molecular epidemiologic analysis
AU2014347768A1 (en) HCV genotyping algorithm

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties